Skip to Content
image description
  • image description
  • image description
  • image description

Cancer Clinical Trials Information at Holy Cross

The Michael and Dianne Bienes Comprehensive Cancer at Holy Cross Hospital in Fort Lauderdale in Broward County (South Florida) offers an extensive panel of research studies, or clinical trials, to those battling breast cancer, colorectal cancer, lung cancer, melanoma (skin cancer), multiple myeloma (cancer of the plasma cells), leukemia (cancer of the blood cells) and other cancers. 

We also offer biomarker-driven trials for which the location of the tumor may not matter. Please scroll to learn more or download the list of open trials

Lung – Advanced, Treatment Experienced


RADIANCE: Resistance and Activating Mutations DIAgnosed Among Non-small Cell Lung Cancer, Community Dwelling, EGFR Mutation Positive Patients.

An open-label, non-randomized, prospective biomarker study to assess analytic concordance and clinical validity between non-invasive testing and tissue testing for EGFR T790M mutation detection in patients with non-small cell lung cancer. 

Contact: Kathy McTague, 954-267-7718 or

Biomarker-driven Lung Cancer Screening (nodule 0.5 cm to 3 cm), or untreated NSCLC

OncoCyte PRO068

A study to evaluate a panel of blood biomarkers for use in patients undergoing evaluation for lung cancer, ONC-LN-44.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or 

Biomarker-driven Trials (location of the cancer may not matter)


An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements.

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or

Bladder – Treatment Naive


A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer

For more information, contact Study Coordinator Mariana Lykoudis at 954-267-7792 or

Brain Cancer – Glioblastoma

M13-813 Intellance 1 Study

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification.

Contact: Mariana Lykoudis, 954-267-7792 or

Breast HER2 Negative

A011502 the ABC Trial

A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or

Breast Hormone receptor-positive, HER2-negative, high risk early stage

CLEE011G2301 (EarLEE-1)

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer 

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or

Breast Registry

CALLER Registry

Collaborative Attempt to Lower Lumpectomy Re-excision Rates. Contact: Dr. Joseph Casey or Eileen Georgi, 954-267-7748 or

Breast Registry

Nipple Sparing Registry

ASBrS Nipple Sparing Mastectomy Registry.

For more information, contact Study Coordinator Eileen Georgi at 954-267-7748 or

Breast – Post-menopausal women with metastatic or advanced breast cancer


An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy.

Contact: Eileen Georgi, 954-267-7748 or

Gastric Cancer


A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors.

Contact Study Coordinator Eileen Georgi at 954-267-7748 or

Genetic Registry

City of Hope Registry

Molecular Genetics Studies of Cancer Patients and Their Relatives.

For more information, contact Eileen Georgi, 954-267-7748 or

Head and Neck Cancer, Early Stage


An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors.

Contact: Eileen Georgi, 954-267-7748 or

Iron Deficiency Anemia


A phase III, randomised, open-label, comparative safety and efficacy trial of intravenous iron isomaltoside (Monofer®) and iron sucrose in subjects with iron deficiency anaemia who are intolerant or unresponsive to oral iron therapy or in whom the haemoglobin measurement in Investigators' opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.

Contact Study Coordinator Mariana Lykoudis at 954-267-7792 or

Lung - Advanced, Treatment Experienced

M16-298 (MERU)

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)

For more information, contact Study Coordinator Kathleen McTague at 954-267-7718 or


Three Women Photo

Cancer risk assessment, screening and prevention programs are vital to educating people about reducing their chances of developing cancer and assessing the need for intervention. Under the direction of our genetic nurse counselor and the Bienes Cancer Center physicians, our Cancer Risk and Prevention Program is for anyone with cancer or a family history of cancer. The vast majority of participants are women who have or have had breast or ovarian cancer, or are at high risk of developing these two cancers. Click to learn more about Genetic Counseling.

Cancer Resources

More Cancer Resources

®2005-2011 WebMD, LLC. All rights reserved.

WebMD does not provide medical advice, diagnosis or treatment.

See additional information.


image description